Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Shell Companies

Financial Services
$10.90 +0.00%

+$0.00 today

Market cap
$264.62M
Beta
0.00
P/E (TTM)
36.7
EPS (TTM)
$0.29
52W Low $10.17High $10.63

Volume 0.00M

Average 0.11M

DMAA Retained Earnings

Cumulative profits kept in the business rather than paid out as dividends.

Drugs Made In America Acquisition Corp. Ordinary SharesNASDAQ: DMAA

Retained Earnings · Q1 FY2026 · quarter ended Mar 2026

Retained earnings remains negative

Q1 FY2026 retained earnings was -$7.38M, compared with -$6.33M a year earlier.

Context

  • Retained earnings amounted to 3.0% of total assets at the end of Q1 FY2026, up 0.3 pp from a year earlier.

What to watch

Whether retained earnings keeps falling in the next quarterly balance sheet after a -16.7% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$7.38M-1.6% QoQ
Last fiscal yearDec 2025
-$7.27M-2603861.6% YoY
Year agoMar 2025
-$6.33M-16.7% since
Retained Earnings past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-16.7%——
1 year-2603861.6%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Retained Earnings history

USD · from the balance sheet

Latest · FY2025
(7.27M) USD
Year-over-year change
-2603861.6%

Retained Earnings vs competitors

How DMAA compares with its peers on the latest reported figures

  • DMAA's Mar 2026 retained earnings of -$7.38M is the 3rd highest of the 10 companies compared; the peer median is -$12.19M.
  • Its year-over-year change of -16.7% is the 5th highest of 10, against a peer median of -172.1%.
  • Retained earnings amounts to 3.0% of total assets for DMAA, versus a peer median of 3.9%.
DMAA Competitors Peer median
Retained Earnings for DMAA and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
SIMASIM Acquisition Corp. IMar 2026-$61.84K +99.4%—0.0%
MLACMountain Lake Acquisition Corp.Mar 2026-$1.13M +83.5%—0.5%
DMAADrugs Made In America Acquisition Corp. Ordinary SharesMar 2026-$7.38M -16.7%—3.0%
OYSEOyster Enterprises II Acquisition CorpMar 2026-$8.1M -11062.9%—3.1%
RTACRenatus Tactical Acquisition Corp I Class A Ordinary SharesMar 2026-$10.28M -9.1%—4.1%
TACOUBerto Acquisition Corp. UnitMar 2026-$12.19M -1511.6%—3.9%
TACOBerto Acquisition Corp.Mar 2026-$12.19M -1511.6%—3.9%
TACHTitan Acquisition Corp.Mar 2026-$13.66M -4119958.4%—4.7%
ALFCenturion Acquisition Corp.Mar 2026-$13.79M -5.2%—4.4%
LOKVLive Oak Acquisition Corp. V Class A Ordinary SharesMar 2026-$30.99M -172.1%—12.8%
Peer median (excluding DMAA) -$12.19M-172.1%—3.9%

Competitors are the stored peer set for DMAA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Drugs Made In America Acquisition Corp. Ordinary Shares

NASDAQ:DMAA

Intrinsic Alpha fair value

Locked

Current Price

$10.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.